Patent ID: 11885812
Assignee: EXAGEN INC.
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 0:
1. A method for treating systemic lupus erythematosus in a human subject in need thereof, wherein the human subject is negative for systemic lupus erythematosus based on a level of double-stranded DNA antibody; the method comprising:
(a) measuring a level of erythrocyte-bound complement component C4d (EC4d) marker in a blood sample obtained from the patient;
(b) measuring a level of B-lymphocyte-bound C4d complement component (BC4d) marker in the blood sample;
(c) measuring a level of anti-nuclear antibody (ANA) in the blood sample;
(d) determining a systemic lupus erythematosus risk score comprising the steps of:
(i) adjusting the level of EC4d by a weighting coefficient to produce a weighted score for EC4d;
(ii) adjusting the level of BC4d by a weighting coefficient to produce a weighted score for BC4d;
(iii) adjusting the level of ANA by a weighting coefficient to produce a weighted score for ANA; and
(iv) combining the weighted score for EC4d, BC4d, and ANA to generate the systemic lupus erythematosus risk score

(e) determining that the human subject has systemic lupus erythematosus based on the systemic lupus erythematosus risk score; and
(f) treating the human subject from step (e) that has systemic lupus erythematosus based on the systemic lupus erythematosus risk score with an effective amount of cyclophosphamide, a corticosteroid, mycophenolate, methotrexate, azathioprine, leflunomide, belimumab, or hydroxychloroquine.